Drugs / PAT-SM6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01727778 | Oct 2012 → Apr 2014 | — | Patrys Ltd. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2016-04-04 | Patrys Ltd. | Results Publication on PAT-SM6 Combination Therapy patrys.com ↗
The combination of PAT-SM6, bortezomib and lenalidomide was tested in a multi-drug resistant MM patient who responded positively, with partial remission of both intra- and extramedullary lesions. |
| 2015-02-03 | Patrys Ltd. | Results PAT-SM6 Phase I/IIa Multiple Myeloma Trial Results Published patrys.com ↗
Safety and tolerability, the primary objectives of this study, have been successfully supported with all doses administered found to be safe, well tolerated and the maximum tolerated dose (MTD) not reached. |
| 2014-08-17 | Patrys Ltd. | Results Patrys to Present at German Hematology Congress patrys.com ↗
The clinical trial data showed that PAT-SM6 was well tolerated with no serious adverse events. |
| 2014-07-23 | Patrys Ltd. | Results Patrys Reports Progress on Preclinical Programmes patrys.com ↗ |
| 2014-06-17 | Patrys Ltd. | Regulatory Patrys Granted Third US Patent for PAT-SM6 patrys.com ↗
Patrys Granted Third US Patent for Lead Clinical Product PAT-SM6 |
| 2014-06-04 | Patrys Ltd. | Results Patrys' CEO Presents at Asia Biotech Invest 2014 patrys.com ↗
PAT-SM6 safe in all patients. |
| 2014-05-27 | Patrys Ltd. | Results Positive Response for PAT-SM6 in Combination Therapy patrys.com ↗
This patient, who has very difficult to treat myeloma, had an excellent response to PAT-SM6 when it was used with other myeloma drugs. |
| 2014-04-01 | Patrys Ltd. | Results First Plant-based Production of PAT-SM6 patrys.com ↗ |
| 2014-03-26 | Patrys Ltd. | Results Final Data Confirms Successful PAT-SM6 Clinical Trial patrys.com ↗
Patrys Limited (ASX: PAB; “the Company”), a clinical stage biotechnology company, is pleased to announce the final results from its Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma (MM). |
| 2014-01-22 | Patrys Ltd. | Results Patrys Provides Shareholder Update patrys.com ↗
The recently completed PAT -SM6 Phase I/IIa clinical trial, in patients with refractory or relapsed multiple myeloma (MM), has successfully achieved the primary endpoint of safety and tolerability. |
All press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PAT-SM6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01727778 ↗ |
| Modality | Monoclonal antibody | “monoclonal immunoglobulin M antibody PAT-SM6” PMID 25637055 ↗ Jan 2015 |
| Route | Intravenous | “Four intravenous infusions of PAT-SM6 at doses of 0.3, 1, 3, and 6 mg/kg within 2 weeks” PMID 25637055 ↗ Jan 2015 |